FoxP3+ Regulatory T-Cell Quantities in Nodal T-Follicular Helper Cell Lymphomas and Peripheral T-Cell Lymphomas Not Otherwise Specified and Their Impact on Overall Survival
Cancers · 29.11.2024 · 16 (23) · 4011
DOI: 10.3390/cancers16234011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 29.11.2024. Verfasst von Eva Erzar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cytopathology, Institute of Oncology Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Slovenian Research and Innovation Agency (ARIS).
Abstract (Originalsprache)
Background/Objectives: The tumour microenvironment (TME) plays an important role in the development and progression of cancer and it differs among lymphomas, both with respect to the composition and quantity of specific tumour-infiltrating immune cells (TICs), such as FoxP3+ regulatory T cells (Tregs). The role of FoxP3+ Tregs in the TME of peripheral T-cell lymphomas (PTCLs) is complex, and their impact on overall survival (OS) remains unclear. Consequently, we aim to evaluate and compare the FoxP3+ cell quantity in nodal PTCLs and reactive lymph nodes (LNs), with a focus on investigating their impact on OS. Methods: excisional lymph node (LN) biopsies from 105 nodal PTCLs and 17 reactive LNs are immunohistochemically stained for FoxP3. Visual scoring of FoxP3+ cells is performed, and different cut-off values are used to evaluate the impact of FoxP3+ cell quantity on OS. Results: FoxP3+ cells are present in the TME of all cases, except for four cases where FoxP3+ is expressed in lymphoma cells. Lower FoxP3+ cell quantities are observed in certain nodal PTCL subtypes compared to reactive LNs. Patients with high FoxP3+ cell quantities show improved OS. However, the FoxP3+ cell quantity is not confirmed as an independent prognostic biomarker. Conclusions: these findings underscore the promise of FoxP3+ cell quantities as added value in prognosis and highlight the potential benefits of Treg-stimulating therapies in PTCLs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cytopathology, Institute of Oncology Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia.
- Medical Faculty, University of Ljubljana, Vrazov Trg 2, 1000 Ljubljana, Slovenia.
- Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Schönbeinstrasse 40, 4031 Basel, Switzerland.
- Division of Medical Oncology, Institute of Oncology Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia.
- Department of Pathology, Institute of Oncology Ljubljana, Zaloška Cesta 2, 1000 Ljubljana, Slovenia.
- Medical Faculty, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia.
ORCID-Profile: Eva Erzar, Alexandar Tzankov, Janja Ocvirk, Lučka Boltežar, Veronika Kloboves Prevodnik, Gorana Gašljević
Förderung
- Slovenian Research and Innovation Agency (ARIS)
Zitieren
APA
Erzar, E., Tzankov, A., Ocvirk, J., Grčar Kuzmanov, B., Boltežar, L., Prevodnik, V. K., & Gašljević, G. (2024). FoxP3+ Regulatory T-Cell Quantities in Nodal T-Follicular Helper Cell Lymphomas and Peripheral T-Cell Lymphomas Not Otherwise Specified and Their Impact on Overall Survival. Cancers, 16(23), 4011. https://doi.org/10.3390/cancers16234011
Vancouver
Erzar E, Tzankov A, Ocvirk J, Grčar Kuzmanov B, Boltežar L, Prevodnik VK, et al. FoxP3+ Regulatory T-Cell Quantities in Nodal T-Follicular Helper Cell Lymphomas and Peripheral T-Cell Lymphomas Not Otherwise Specified and Their Impact on Overall Survival. Cancers. 2024;16(23):4011. doi:10.3390/cancers16234011
BibTeX
@article{Erzar2024,
author = {Erzar, Eva and Tzankov, Alexandar and Ocvirk, Janja and Grčar Kuzmanov, Biljana and Boltežar, Lučka and Prevodnik, Veronika Kloboves and Gašljević, Gorana},
title = {FoxP3+ Regulatory T-Cell Quantities in Nodal T-Follicular Helper Cell Lymphomas and Peripheral T-Cell Lymphomas Not Otherwise Specified and Their Impact on Overall Survival},
journal = {Cancers},
year = {2024},
volume = {16},
number = {23},
pages = {4011},
doi = {10.3390/cancers16234011}
}
EUVIMED